- Home
- NRDS vs IMTX Comparison
NRDS vs IMTX Comparison
Compare NRDS & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDS
- IMTX
- Stock Information
- Founded
- NRDS 2009
- IMTX N/A
- Country
- NRDS United States
- IMTX Germany
- Employees
- NRDS N/A
- IMTX N/A
- Industry
- NRDS EDP Services
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRDS Technology
- IMTX Health Care
- Exchange
- NRDS Nasdaq
- IMTX Nasdaq
- Market Cap
- NRDS 810.0M
- IMTX 653.9M
- IPO Year
- NRDS 2021
- IMTX N/A
- Fundamental
- Price
- NRDS $10.59
- IMTX $6.00
- Analyst Decision
- NRDS Buy
- IMTX Strong Buy
- Analyst Count
- NRDS 6
- IMTX 4
- Target Price
- NRDS $15.17
- IMTX $14.67
- AVG Volume (30 Days)
- NRDS 417.1K
- IMTX 678.9K
- Earning Date
- NRDS 07-30-2025
- IMTX 08-12-2025
- Dividend Yield
- NRDS N/A
- IMTX N/A
- EPS Growth
- NRDS N/A
- IMTX N/A
- EPS
- NRDS 0.38
- IMTX N/A
- Revenue
- NRDS $734,900,000.00
- IMTX $155,801,989.00
- Revenue This Year
- NRDS $18.07
- IMTX N/A
- Revenue Next Year
- NRDS $8.22
- IMTX $1.92
- P/E Ratio
- NRDS $28.05
- IMTX N/A
- Revenue Growth
- NRDS 24.20
- IMTX 93.56
- 52 Week Low
- NRDS $7.55
- IMTX $3.30
- 52 Week High
- NRDS $16.45
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- NRDS 42.52
- IMTX 61.02
- Support Level
- NRDS $11.07
- IMTX $5.50
- Resistance Level
- NRDS $11.49
- IMTX $6.17
- Average True Range (ATR)
- NRDS 0.32
- IMTX 0.28
- MACD
- NRDS -0.04
- IMTX 0.02
- Stochastic Oscillator
- NRDS 13.19
- IMTX 81.38
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.